Ireland
--:--IST
Latest
Clinical Trials in France / NCT05685069
Recruiting Observational

Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions

NCT05685069 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2019-03-01
Last updated
2024-11-14

Condition(s) studied

Silent StrokeSilent Cerebral InfarctCovert Brain InfarctCovert Brain InfarctionLacuneSilent Brain Infarction

Study summary

The CBI registry is a prospective, interdisciplinary, multimodal observational registry of patients with covert brain infarction. Methods: A standardized workup in analogy to manifest ischemic stroke including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, laboratory work-up and risk factor assessment as well as noninvasive angiography of the cervical and intracranial arteries will be performed.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either: * DWI positive lesions: Focus of restricted diffusion (high DWI signal and low ADC value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for MS OR * Cavitatory Lesions: ≥ 3 mm in size that follow CSF on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR * T2W hyperintense/T1W hypointense lesions: Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR present within cortical gray matter or deep gray matter nuclei OR a lesion that is new, compared with an MRI performed within 3 months OR T2W hyper/T1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for MS or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning * Informed Consent as documented by signature by patient or legally authorized representative Exclusion Criteria: * Projected life expectancy of less than 2 years, * Contraindication to MRI, * Patients with a history of symptoms compatible with an AIS/TIA attributable to the lesion observed, covert neurological deficits are allowed, * Patient is already included in another clinical trial that will affect the objectives of this study, * Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly, * Women who are pregnant or breast feeding or intention to become pregnant during the course of the study, * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Contraindications to any of the routine procedures, e.g. inability to obtain neurovascular ultrasound examination, * Known or suspected non-compliance, drug or alcohol abuse

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre Hospitalier Universitaire de Tours Tours France Recruiting
Inselspital Bern Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05685069 on ClinicalTrials.gov ↗ ← All trials in France